Filing Details
- Accession Number:
- 0001415889-22-011065
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-03 16:52:05
- Reporting Period:
- 2022-11-01
- Accepted Time:
- 2022-11-03 16:52:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 815094 | Abiomed Inc | NASD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1931998 | T. Matthew Plano | C/O Abiomed, Inc., 22 Cherry Hill Drive Danvers MA 01923 | Vp, Global Operations | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock $.01 Par Value | Acquisiton | 2022-11-01 | 1,843 | $223.90 | 13,814 | No | 4 | M | Direct | |
| Common Stock $.01 Par Value | Disposition | 2022-11-01 | 974 | $377.84 | 12,840 | No | 4 | S | Direct | |
| Common Stock $.01 Par Value | Disposition | 2022-11-01 | 1,699 | $378.61 | 11,141 | No | 4 | S | Direct | |
| Common Stock $.01 Par Value | Disposition | 2022-11-01 | 722 | $379.33 | 10,419 | No | 4 | S | Direct | |
| Common Stock $.01 Par Value | Disposition | 2022-11-01 | 149 | $380.22 | 10,270 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-11-01 | 1,843 | $0.00 | 0 | $223.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 922 | 2021-05-29 | 2030-05-29 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | $381.97 | 2019-05-16 | 2028-05-16 | 0 | 2,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $266.39 | 2020-05-30 | 2029-05-30 | 0 | 5,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $283.88 | 2022-05-25 | 2031-05-25 | 0 | 2,765 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2028-05-16 | 0 | 2,000 | Direct |
| 2029-05-30 | 0 | 5,000 | Direct |
| 2031-05-25 | 0 | 2,765 | Direct |
Footnotes
- Exercise of stock options pursuant to reporting owners 10b5-1 plan.
- Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- This price represents the sale price of the transactions on the reported date at $377.8389. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the sale price of the transactions on the reported date at $378.6120. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the sale price of the transactions on the reported date at $379.3305. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the sale price of the transactions on the reported date at $380.2151. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 2
Billionaire Hedge Funds
